FDA Launches Mifepristone Safety Study Critics Call Politically Loaded

The FDA just kicked off a six-month safety review of mifepristone — a drug it first approved 26 years ago, in 2000. The Wall Street Journal broke the news, and Scientific American’s Jackie Flynn Mogensen filled in the alarms from health experts who see this as political theater dressed in lab coats.

Why This Review Smells Like a Setup

Peter Lurie, a former associate commissioner for public health strategy and analysis at the FDA, put it bluntly last October: “Based on what we have seen from this administration to date, there is every reason to fear that this study will be a cherry-picking, data-contorting exercise designed to support a predetermined conclusion of lack of safety.” That quote is from a Scientific American piece, and Lurie wasn’t guessing — he ran public health strategy at the agency.

Secretary of Health and Human Services Robert F. Kennedy Jr. announced plans to review mifepristone’s safety last year, citing concerns about pandemic-era telehealth policies that allowed the pill to be prescribed remotely. Antiabortion advocates complained about the slow pace; now the FDA is accelerating. The agency insists it’s “science-based.” I’m not buying that given the track record.

What’s at Stake: Telehealth and Access

Mifepristone is currently available by mail, but that hangs by a legal thread. Last month the Supreme Court extended a stay on a lower court ruling that would have banned mailing the drug nationwide. If the mail-order channel gets shut down, doctors can switch to misoprostol alone — but that comes with added side effects and more complications, increasing the burden on both patients and prescribers.

The review will examine the REMS (risk evaluation and mitigation strategy) for mifepristone. The FDA spokesperson says it’s been “actively working on a science-based safety review for months” and that reporting “a study is just being started” is false. But sources told the WSJ the review will take about six months, with results likely after the November midterm elections. Coincidence? I don’t think so.

The Timing Tells the Story

Six months puts the finish line right after the midterms — meaning the administration gets to release findings without immediate electoral blowback. That’s a classic political move, not a scientific one. The drug’s safety record is well-established: mifepristone has been used by millions of women since 2000 with a complication rate lower than that of many common antibiotics. Any review that ignores that body of evidence is an exercise in policy, not medicine.

Lurie’s warning stands: this is a cherry-picking, data-contorting operation. If the results come out as predicted, the real test will be whether courts or the medical community call it what it is.

Source: Report: FDA just launched a study on the abortion pill
Domain: scientificamerican.com